The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic value of PAM50 in residual breast cancer following neoadjuvant endocrine therapy (NET): A retrospective analysis with long follow-up.
 
Miguel J. Gil Gil
Honoraria - Novartis; Pfizer; Pierre Fabre; Roche
Consulting or Advisory Role - Daiichi Sankyo; Novartis; Pfizer
Travel, Accommodations, Expenses - Daiichi Sankyo; Roche
 
Francisco Javier Perez
No Relationships to Disclose
 
Teresa Soler Monso
No Relationships to Disclose
 
Tomas Pascual
No Relationships to Disclose
 
Patricia Galván
No Relationships to Disclose
 
Laia Pare
No Relationships to Disclose
 
Anna Petit
No Relationships to Disclose
 
Catalina Falo
Travel, Accommodations, Expenses - Pfizer
 
Agostina Stradella
Consulting or Advisory Role - Celgene; Roche
Expert Testimony - Celgene; Roche
Travel, Accommodations, Expenses - Roche
 
María Jesús Pla
No Relationships to Disclose
 
Ramon Salazar
Leadership - Sace Medhealth
Stock and Other Ownership Interests - Sace Medhealth
Consulting or Advisory Role - Amgen; Amgen; AstraZeneca; Celgene; Guardant Health; Ipsen; Lilly; Merck; Merck Serono; MSD; Novartis; Pfizer; Roche; Roche; VCN Biosciences
Speakers' Bureau - Amgen; Novartis; Roche
Research Funding - Roche
Travel, Accommodations, Expenses - Amgen; Ipsen; Merck; Novartis; Roche
 
Aleix Prat
Employment - Novartis (I)
Honoraria - Daiichi Sankyo; Lilly; MSD Oncology; Novartis; Pfizer; Roche
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; NanoString Technologies (Inst); Novartis; Pfizer; Roche
Research Funding - Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics